ArticleMolecules (Basel, Switzerland)2021
Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.
Viet Hung Dao, Isabelle Ourliac-Garnier, Cédric Logé, Florence O McCarthy, Stéphane Bach, Teresinha Gonçalves da Silva, Caroline Denevault-Sabourin, Jérôme Thiéfaine, Blandine Baratte, Thomas Robert and 4 more
Open access · goldAbstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors at 5 institutions in 4 countries.
Viet Hung DaoCibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Université de Nantes, 44000 Nantes, France.ORCID 0000-0002-5077-5192 Isabelle Ourliac-GarnierCibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Université de Nantes, 44000 Nantes, France.ORCID 0000-0002-8159-0959 Cédric LogéCibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Université de Nantes, 44000 Nantes, France.ORCID 0000-0001-5113-6547 Florence O McCarthySchool of Chemistry, Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, T12 K8AF Cork, Ireland.ORCID 0000-0001-5837-1638 Stéphane BachSorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France.ORCID 0000-0002-7186-7483 Teresinha Gonçalves da SilvaDepartamento de Antibióticos, Universidade Federal de Pernambuco, Recife 50670-901, PE, Brazil.ORCID 0000-0002-5971-0029 Caroline Denevault-SabourinEA GICC-ERL 7001 CNRS, Team IMT, University of Tours, 37200 Tours, France.ORCID 0000-0002-9901-7608 Jérôme ThiéfaineCibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Université de Nantes, 44000 Nantes, France.
Blandine BaratteSorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France.ORCID 0000-0002-2064-9558 Thomas RobertSorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France.
Fabrice GouilleuxCNRS ERL7001 LNOx «Leukemic Niche and redOx Metabolism», EA GICC, University of Tours, 37000 Tours, France.ORCID 0000-0001-6047-1718 Marie Brachet-BotineauCNRS ERL7001 LNOx «Leukemic Niche and redOx Metabolism», EA GICC, University of Tours, 37000 Tours, France.
Marc-Antoine BazinCibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Université de Nantes, 44000 Nantes, France.ORCID 0000-0003-0987-5404 Pascal MarchandCibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Université de Nantes, 44000 Nantes, France.ORCID 0000-0001-7773-8642 Cibles et Médicaments des Infections et de l'ImmunitéCentre National de la Recherche Scientifique · FRUniversité de Tours · FRUniversidade Federal de Pernambuco · BRUniversity College Cork · IE
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Pim kinases (proviral integration site for Moloney murine leukemia virus kinases) are overexpressed in various types of hematological malignancies and solid carcinomas, and promote cell proliferation and survival. Thus, Pim kinases are validated as targets for antitumor therapy. In this context, our combined efforts in natural product-inspired library generation and screening furnished very promising dibenzo[
Indexed as
AnimalsAntineoplastic AgentsBenzofuransCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHumansModels, MolecularMolecular StructureMothsProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProto-Oncogene Proteins c-pim-1Tumor Cells, CulturedAntineoplastic AgentsBenzofuranscercosporamideClk dual-specificity kinasesdibenzofuranProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProto-Oncogene Proteins c-pim-1proto-oncogene proteins pimanticancer agentscercosporamideCLK1 kinasedibenzo[b,d]furankinase inhibitorsPim kinases
Identifiers
PMID34770981
PMCPMC8587151
OpenAlexW3208654231
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390